Composite and surrogate outcomes in randomised controlled trials
- PMID: 17431231
- PMCID: PMC1852018
- DOI: 10.1136/bmj.39176.461227.80
Composite and surrogate outcomes in randomised controlled trials
Abstract
Composite end points may mislead—and regulators allow it to happen
Conflict of interest statement
Comment on
-
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.BMJ. 2007 Apr 14;334(7597):786. doi: 10.1136/bmj.39136.682083.AE. Epub 2007 Apr 2. BMJ. 2007. PMID: 17403713 Free PMC article.
References
-
- Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007. doi: 10.1136/bmj.39136.682083.AE - DOI - PMC - PubMed
-
- Moyé LA. End-point interpretation in clinical trials: the case for discipline. Control Clin Trials 1999;20:40-9. - PubMed
-
- Khan SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. - PubMed
-
- Reuters. Glaxo sees new study boosting Avandia, Avandamet 4 Dec 2006. www.reuters.com/article/idUSL0440072620061204.
-
- Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials—greater precision but with greater uncertainty? JAMA 2003;289:2554-9. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources